CUE
CUE BIOPHARMA INC
$3.38
Earnings Summary
Revenue | $0.48Mn |
Net Profits | $-11.1Mn |
Net Profit Margins | -2335.86% |
Highlights
CUE BIOPHARMA INC’s revenue fell -54.7% since last year same period to $0.48Mn in the Q4 2020. On a quarterly growth basis, CUE BIOPHARMA INC has generated -32.48% fall in its revenue since last 3-months.
CUE BIOPHARMA INC’s net profit fell -24.51% since last year same period to $-11.1Mn in the Q4 2020. On a quarterly growth basis, CUE BIOPHARMA INC has generated -10.69% fall in its net profits since last 3-months.
CUE BIOPHARMA INC’s net profit margin fell -174.88% since last year same period to -2335.86% in the Q4 2020. On a quarterly growth basis, CUE BIOPHARMA INC has generated -63.94% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the CUE BIOPHARMA INC post its latest quarter earnings
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Current Year | -0.34 |
Highlights
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 10.53% jump from last quarter’s estimates.
CUE BIOPHARMA INC’s earning per share (EPS) estimates for the current year stand at -0.34.
Key Ratios
Key ratios of the CUE BIOPHARMA INC post its Q3 2022 earnings
Earning Per Share (EPS) | -0.31 |
Return on Assets (ROA) | -0.37 |
Return on Equity (ROE) | -0.82 |
Highlights
CUE BIOPHARMA INC’s earning per share (EPS) jumped 24.39% since last year same period to -0.31 in the Q3 2022. This indicates that the CUE BIOPHARMA INC has generated 24.39% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CUE BIOPHARMA INC’s return on assets (ROA) stands at -0.37.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CUE BIOPHARMA INC’s return on equity (ROE) stands at -0.82.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-08-08 | -0.56 | -0.46 | 17.86% |
2019-05-08 | -0.4 | -0.54 | -35% |
2019-11-07 | -0.44 | -0.31 | 29.55% |
2020-03-12 | -0.45 | -0.36 | 20% |
Company Information
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.
Organisation | CUE BIOPHARMA INC |
Headquarters | 21 Erie Street, Cambridge, MA, United States, 02139 |
Employees | 57 |
Industry | Health Technology |
CEO | Daniel Passeri |
Discover More Earning Stocks in Health Technology Sector
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*